× About the Journal Scope of the Journal SPER Publications Editorial Board Abstracting and Indexing Articles in Press Current Issue Archives Submit Article Author Guidelines Advertise Join as Reviewer Contact Editorial Policies and Peer Review Process Journal Policies Publishing Ethics

Original Article
Year : 2021  |  Volume : 9  |  Issue : 4  |  Page : 49-71

Formulation and evaluation of febuxostat nanoemulsion for transdermal drug delivery

The aim of the present study was to investigate the potential of nanoemulsion formulations for transdermal delivery of febuxostat. Among the various excipients tested, based on solubility study Capmul MCM, tween 80, and Transcutol P, were selected as oil, surfactant, and cosurfactant, respectively. The nanoemulsions region was identified by constructing pseudo-ternary phase diagram using aqueous phase titration. The prepared nanoemulsion was subjected to different thermodynamic stability study, and the nanoemulsion that passed thermodynamic stability tests were evaluation for viscosity, refractive index, droplet size, polydispersity index (PDI), transmission electron microscopy, and in vitro permeation study using human cadaver skin. On the basis of evaluation neutral (NE) (Z1) formulations which consist of 1.0% w/w of drug, 6.711% w/w of oil phase, 60.402% w/w of Smix, and 32.885% w/w of distilled water were selected as an optimized formulation. The mean droplet size of NE (Z1) formulation was lower (55 nm) as compared to other formulation studied. The PDI (0.33) and viscosity (30.22 ± 0.86 cp) of formulation NE (Z1) were lower as compared to other formulations. A significant increase in steady-state flux (jss) was observed in nanoemulsion NE (Z1). In conclusion, nanoemulsion could be a promising system to improve the transdermal efficacy of the febuxostat.
Print this article     Email this article


Contact SPER Publications

SPER Publications and Solutions Pvt. Ltd.

#709, Tower B, Noida One,
Sector 62, Noida,
Uttar Pradesh 201301 [Delhi-NCR] India
Phone: +91-120-410-0035